[SCHEDULE 13G/A] Evommune, Inc. Amended Passive Investment Disclosure
Evommune stake of 3.9% reported by Andera group
Evommune, Inc. received an amended Schedule 13G disclosure from BioDiscovery 6 FPCI, Andera Partners, Stephane Bergez and Francois Xavier Mauron regarding their holdings of Evommune common stock.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Evommune, Inc. received an amended Schedule 13G disclosure from BioDiscovery 6 FPCI, Andera Partners, Stephane Bergez and Francois Xavier Mauron regarding their holdings of Evommune common stock. BioDiscovery 6 is the record holder of 1,391,990 shares of common stock, which the reporting persons may be deemed to beneficially own through Andera as management company and its managing partners, Bergez and Mauron.
This position represents 3.9% of Evommune’s common stock, based on 36,018,372 shares outstanding as of May 5, 2026. The reporting persons report shared voting and dispositive power over 1,391,990 shares and no sole voting or dispositive power. They state that they own 5% or less of the class and expressly disclaim status as a group.
Key Figures
Beneficially owned shares:1,391,990 sharesPercent of class:3.9%Shares outstanding:36,018,372 shares+2 more
5 metrics
Beneficially owned shares1,391,990 sharesShares of Evommune common stock beneficially owned as of June 30, 2026
Percent of class3.9%Portion of Evommune common stock beneficially owned, based on shares outstanding
Shares outstanding36,018,372 sharesEvommune common shares outstanding as of May 5, 2026
Shared voting power1,391,990 sharesShares over which reporting persons have shared voting power
Shared dispositive power1,391,990 sharesShares over which reporting persons have shared dispositive power
Key Terms
beneficially own, shared voting power, shared dispositive power, percent of class, +1 more
5 terms
beneficially ownfinancial
"may be deemed to beneficially own the securities held by BioDiscovery 6"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting powerfinancial
"Shared Voting Power 1,391,990.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 1,391,990.00"
percent of classfinancial
"Ownership of 5 Percent or Less of a Class."
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
Schedule 13Gregulatory
"Exhibit 99.1 Joint Filing Agreement to the Reporting Persons' Schedule 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Evommune (EVMN) does BioDiscovery 6 and Andera report owning?
They report beneficial ownership of 3.9% of Evommune’s common stock, based on 36,018,372 shares outstanding as of May 5, 2026. This percentage is disclosed in the Schedule 13G/A as of June 30, 2026.
How many Evommune (EVMN) shares are beneficially owned by the reporting persons?
The reporting persons may be deemed to beneficially own 1,391,990 shares of Evommune common stock. BioDiscovery 6 FPCI is the record holder of these shares, with investment decisions made by its management company, Andera Partners.
Do the BioDiscovery 6 and Andera group have voting control over Evommune (EVMN) shares?
They report shared voting power over 1,391,990 shares and no sole voting power. Voting and dispositive decisions for these Evommune shares are made by Andera Partners as management company of BioDiscovery 6.
Are the BioDiscovery 6 and Andera reporting persons a group for Evommune (EVMN) under SEC rules?
They expressly disclaim status as a “group” for purposes of beneficial ownership reporting. However, each may be deemed to beneficially own the Evommune shares held by BioDiscovery 6 as described in the Schedule 13G/A.
What is the ownership threshold status disclosed for Evommune (EVMN) in this Schedule 13G/A?
The filing states ownership of 5 percent or less of a class of Evommune common stock. The reported 3.9% stake reflects this, calculated against 36,018,372 outstanding shares as of May 5, 2026.
Who are the individuals associated with the Evommune (EVMN) stake reported by BioDiscovery 6?
The reporting persons include Stephane Bergez and Francois Xavier Mauron, managing partners of Andera Partners. Through Andera’s role managing BioDiscovery 6, they may be deemed to beneficially own the 1,391,990 Evommune shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
EVOMMUNE, INC.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
30054Y107
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
30054Y107
1
Names of Reporting Persons
Andera Partners
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
FRANCE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,391,990.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,391,990.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,391,990.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
30054Y107
1
Names of Reporting Persons
BioDiscovery 6 FPCI
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
FRANCE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,391,990.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,391,990.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,391,990.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
30054Y107
1
Names of Reporting Persons
Stephane Bergez
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
FRANCE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,391,990.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,391,990.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,391,990.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
30054Y107
1
Names of Reporting Persons
Francois Xavier Mauron
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
FRANCE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,391,990.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,391,990.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,391,990.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
EVOMMUNE, INC.
(b)
Address of issuer's principal executive offices:
1841 Page Mill Road, Suite 100, Palo Alto, CA, 94304.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
BioDiscovery 6 FPCI ("BioDiscovery 6")
Andera Partners ("Andera")
Stephane Bergez ("Bergez")
Francois Xavier Mauron ("Mauron")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
2 place de Rio de Janeiro
75008 Paris
France
(c)
Citizenship:
BioDiscovery 6 France
Andera France
Bergez France
Mauron France
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
30054Y107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
BioDiscovery 6 is the record holder of 1,391,990 shares of common stock. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6.
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 36,018,372 shares outstanding as of May 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 7, 2026
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as June 30, 2026 and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Andera Partners
Signature:
/s/ Stephane Bergez
Name/Title:
By Stephane Bergez, Managing Partner
Date:
08/14/2026
BioDiscovery 6 FPCI
Signature:
/s/ Stephane Bergez
Name/Title:
By Andera Partners, its management company, By Stephane Bergez, Managing Partner
Date:
08/14/2026
Stephane Bergez
Signature:
/s/ Stephane Bergez
Name/Title:
Stephane Bergez
Date:
08/14/2026
Francois Xavier Mauron
Signature:
/s/ Francois Xavier Mauron
Name/Title:
Francois Xavier Mauron
Date:
08/14/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on November 17, 2025).
